Novartis (NVS) announced that its breast cancer pill LEE011 has won breakthrough therapy designation from U.S. regulators as a first-line treatment for an advanced form of breast cancer. The FDA granted the designation in combination with letrozole for treating hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.